effective in MD without noticeable neuropsychological adverse effects, These results should however be viewed as preliminary. Furthermore the clinical relevance of these findings is not obvious since the effect size was small to medium. Thus more studies are needed to assess the long term efficacy and overall clinical benefit of rTMS in MD and characterize optimal treatment parameters. The studies were supported by grants from the Stanley Foundation and NARSAD.

S25.5

Transcranial magnetic stimulation and depression

T.G. Bolwig*. Department of Psychiatry, Copenhagen University Hospital, Denmark

Transcranial Magnetic Stimulation (TMS) has been used in the therapy of depression during the last 6 years. No direct comparison between ECT and TMS has been made. ECT and TMS both use electrical energy to induce neuropsychiatric change. Up to date there are few trials comparing ECT with TMS. Grunhaus et al (2000) looked at non-responders to unilateral ECT and found no difference in response to either bilateral ECT or TMS while they found ECT significantly more effective than TMS for patients with psychotic depression. The current delivered with TMS generators can be directed to particular regions (rTMS) while ECT involves all regions of the brain. rTMS may be given as high frequency stimulation (higher than 1 Hz) and as low frequency or singlestimulation TMS (0.25 to 1.0 Hz). Using low frequency rTMS Klein et al 1999 found evidence for short-term efficacy of this modification in patients with recurrent major depression. Using high-frequency rTMS George et al 1997 found a small difference in antidepressant effect in patients having active rTMS to the left dorsolateral prefrontal cortex compared with sham-rTMS.

A recent study (Lisanby et al 2001) demonstrated that rTMS may be used in such a way that generalised seizures are induced and are therapeutic.

The antidepressant effect of rTMS should be considered further optimising stimulus frequency, intensity and magnetic coil placement, which has not yet been optimised. Further a biological heterogeneity among patients treated with rTMS may also contribute to differing efficacy across clinical studies.

S25.6

Transcranial magnetic stimulation as a tool for assessment and modulation of cortical excitability in patients with major depression

A.V. Chistyakov*, B. Kaplan, H. Häfner, D. Koren, M. Feinsod, E. Klein. Rambam Medical Center, B. Rappaport Faculty of Medicine, Technion IIT, Haifa, Israel

Introduction: Since its introduction (Barker et al., 1985), single-pulse transcranial magnetic stimulation (sTMS) has been widely used as a noninvasive technique to evaluate brain function in health and disease. More recently, repetitive transcranial magnetic stimulation (rTMS) was introduced as a tool for modulating brain activity. High frequency rTMS (3Hz and higher) has been shown to enhance cortical excitability while low frequency (1Hz) rTMS has been reported to transiently inhibit focal cortical areas. The capacity of rTMS to alter cortical excitability may play an important role in mechanisms of its antidepressant effects. However, the relationship between stimulus location, frequency and treatment outcome is still not clear and objective measures that could help to optimize treatment are lacking. Objective: To study changes in

cortical excitability following rTMS treatment in patients with major depression (MD) and their relationship with rTMS parameters and treatment outcome.

Methods: Forty eight consenting subjects with MD were randomized to receive 1) right prefrontal rTMS with placebo medication (N=21), or 2) left prefrontal rTMS with placebo medication (N=16) or 3) active medication with sham rTMS (N=11). Patient groups were further divided into subgroups according to the frequency of rTMS: 1) Twenty four patients received ten daily rTMS treatments at 3Hz frequency and 110% motor threshold intensity; 2) Thirteen patients received ten daily rTMS treatments at 10Hz frequency and 100% motor threshold intensity. Severity of depression was blindly assessed before, during and after treatment. In order to assess the effect of rTMS on cortical excitability, the resting motor threshold (rMT), silent period threshold (SPT), silent period duration (SPD) and amplitude of the motor evoked potential (MEP/M- wave amplitude ratio) in response to sTMS were evaluated before and after the treatment.

Results: Left prefrontal 3Hz rTMS was superior to the other treatments. Following two weeks of left rTMS a significant increase of the left motor cortex MEP/M wave amplitude ratio was evidenced in the patients who improved but not in those who failed to improve (p<0.05). No changes were observed in the patients who received right or sham rTMS.

Conclusions: The antidepressant effect of rTMS seems to be associated with increase of the left hemisphere excitability. Objective measures of cortical excitability could help to optimize treatment and might become a useful predictor of treatment outcome.

S26. Neuromuscular abnormalities in schizophrenia – a consequence of central or peripheral mechanisms

Chairs: H.Y. Meltzer (USA), F.-A. Wiesel (S)

S26.1

Neuromuscular abnormalities in psychosis; implications for nosology, neurodevelopment and neurotransmitter abnormalities

H.Y. Meltzer*. Vanderbilt University Medical Center, Department of Psychiatry, Nashville, TN, USA

Some but not all patients with schizophrenia, schizoaffective disorder, and to a lesser extent, bipolar disorder and psychotic depression, have been reported to have various abnormalities of the neuromuscular system, including: 1)small-moderate increases in plasma creatine kinase (CK) activity of skeletal muscle origin during a brief period associated with recent onset of delusions and hallucinations; 2)various types of morphologic abnormalities of skeletal muscle fibers, including denervated fibers and increased fiber type grouping; 3)increased branching and sprouting of subterminal motor nerves and increased motor unit territory; 4) motor nerve conduction deficits; and 5) infant and childhood gross motor abnormalities. These findings suggest a possible neurodevelopmental etiology. The commonality of these abnormalities across psychotic illnesses suggests nosologic overlap. Massive increases in plasma CK activity with antipsychotic drugs, particularly atypical antipsychotic drugs, have been reported in a small proportion of patients. The discovery of 5-HT2A receptors in skeletal muscle cell, along with other data, raises the possibility that serotonin is important for neuromuscular abnormalities in psychosis.